Introduction/Background The standard treatment for advanced stages of cervical cancer (IB2-IV) is the combination of concomitant radiochemotherapy (RCT) and brachytherapy. Hysterectomy is an option in therapeutic guidelines, but its place is debated. This surgery is controversial because of its unproven benefit and its morbidity. The objectives of this study were to demonstrate the morbidity of closure hysterectomy, study the complications and their risk factors, demonstrate the post-surgical prognosis and define the place, interest and indications of hysterectomy in the therapeutic arsenal for this pathology.

Methodology We carried out a descriptive retrospective cohort of an observational study oof 86 patients treated from stage IB2 to stage IV cervical cancer between 2021 and 2022. All patients in our population were treated with RCC +/- brachytherapy followed by surgery.

Results In our series, our patients were treated for cervical cancer (CE in 88.4% and ADK in 11.6%) of advanced stage IIB (56,98%), IIA (15,12%), IB2 (10,47%) IIIC1 (5,81%), IIIB (4,65%), IVA (4,65%) and IIIC2 (2,33%).

Radiotherapy was carried out in all patients, an average dose of 48.78 Gy was administered, of which the vast majority of patients (90.7%) received a dose between 40 and 50 Gy.

50 patients (58.1%) received brachytherapy. 82 of the patients (95.3%) received chemotherapy (concomitant in 78 patients). The average time from CRT to surgery was 11.96 weeks. Closure hysterectomy was enlarged (ACHE) in 82.2% of cases, with a surgical approach by laparotomy in 91.8% of cases.

Conclusion Our study shows a relatively low and acceptable rate of complications from closure surgery given the absence of severity and the low grade of these complications according to the different classifications . Our study shows that hysterectomy provides significant benefits in the final result of the treatment of this disease.

Disclosures Nothing to disclose.